Innovative Microbiome Platform AMILI operates the leading precision gut microbiome platform in Southeast Asia, providing advanced microbiome analysis and banking services, which presents opportunities to collaborate with healthcare providers seeking cutting-edge microbiome solutions.

Strong Funding Backing With a recent Series A funding of 10.5 million US dollars, AMILI demonstrates solid financial backing and growth potential, making it a promising partner for expanding microbiome-based health services across the region.

Healthcare Partnerships Amili’s collaborations with established healthcare entities like Cordlife highlight a strategic path into medical and wellness sectors, offering potential opportunities to integrate microbiome therapies into patient care and wellness programs.

Market Expansion Based in Singapore with regional ambitions, Amili’s growth trajectory indicates a need for supportive products, technology integration, and infrastructure investments to accelerate its presence in Southeast Asia and Greater Asia.

Targeted Customer Base With a relatively lean team of under 200 employees and a focus on precision health, Amili offers opportunities for tailored solutions, digital health tools, and professional education initiatives aimed at healthcare professionals and researchers interested in microbiome science.